^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anktiva (nogapendekin alfa inbakicept-pmln)

    i
    Other names: ALT-803, IL-15N72D:IL-15RαSu/Fc fusion protein complex, ALT 803, N-803, IL-15N72D:IL-15RαSu/IgG1 Fc complex
    Company:
    ImmunityBio
    Drug class:
    IL-15 superagonist
    Related drugs:
    11d
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, University of Utah | Trial completion date: Sep 2031 --> Dec 2031 | Trial primary completion date: Sep 2030 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    13d
    FLINN: First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    24d
    The Quadruple Immunotherapy for Colorectal Cancer (QuICC) Trial for Mismatch Repair-Proficient Metastatic Colorectal Cancer. (PubMed, Oncologist)
    Quadruplet therapy produced one objective response in unselected mCRC patients (n = 20). There were no responses with triplet therapy (n = 12). The role of ICB-based combination immunotherapy in pMMR CRC remains unclear. NCT04491955.
    Journal • Mismatch repair • pMMR
    |
    MUC1 (Mucin 1) • TGFB1 (Transforming Growth Factor Beta 1) • IL15 (Interleukin 15)
    |
    RAS wild-type
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
    2ms
    The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803. (PubMed, Cancer Immunol Immunother)
    Enhanced avelumab-mediated antibody-dependent cell-mediated cytotoxicity and lysis by PD-L1 targeting high-affinity NK (PD-L1 t-haNK) cells were observed in tuvusertib-treated DU145. In vivo in the DU145 PCa xenograft model, tuvusertib and N-803 combination therapy demonstrated marked and significant antitumor efficacy relative to either monotherapy, eliciting superior tumor growth control and prolonging survival. Our findings support further investigation into the use of ATRi with immune checkpoint blockade and/or immune-stimulating agents in prostate cancer.
    Journal
    |
    BCL2L1 (BCL2-like 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL15 (Interleukin 15) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • NKG2D (killer cell lectin like receptor K1)
    |
    Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • tuvusertib (M1774) • PD-L1.t-haNK
    2ms
    3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Rockefeller University | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Washington University School of Medicine | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Sep 2026 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=328, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Oct 2025 --> May 2026
    Trial completion date
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK • aldoxorubicin (INNO-206)
    2ms
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    2ms
    N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy (clinicaltrials.gov)
    P1, N=8, Not yet recruiting, Northwestern University
    New P1 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P1/2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2028 --> Oct 2030 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Zynyz (retifanlimab-dlwr) • SX-682 • Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, University of Utah | Initiation date: Sep 2025 --> Dec 2025
    Trial initiation date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=34, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK